Skip to main content

Table 2 Characteristics of the study population

From: Can multiple SNP testing in BRCA2 and BRCA1 female carriers be used to improve risk prediction models in conjunction with clinical assessment?

Variable Median (interquartile range) or N (%)
  BRCA1 BRCA2
  Menopause (n = 200) Ovulating (n = 113) All (n = 548)* Menopause (n = 195) Ovulating (n = 93) All (n = 523)*
Year of birth 1955 (1946-1962) 1963 (1952-1979) 1959 (1948-1969) 1952 (1944-1959) 1963 (1952-1971) 1957 (1947-1966)
Manchester score 32 (22.5-40) 28 (20-38) 29 (20-40.75) 26 (20-35) 27 (20-36) 26 (20-35)
BMI 24.07 (22.34-28.18) 22.52 (21.39-26.71) 23.7 (21.6475-27.3125) 25.12 (22.52-28.565) 24.225 (21.975-27.02) 24.84 (22.355-28.305)
Parity 2 (2-3) 1 (0-2) 2 (1-3) 2 (0-9) 2 (0-9) 2 (0-9)
Age of menarche 13 (12-14.25) 13 (12-14) 13 (12-14) 13 (12-14) 13 (12-14) 13 (12-14)
Age of menopause 43 (38-46) 44 (40-48)** 43 (39-47)** 45 (40.5-48.5) 45 (39.5-49.5)** 45 (40-49)**
Age of full-term pregnancy 24 (21-28) 23 (20-26.25) 24 (21-28) 24 (21-28) 23 (20.25-27) 24 (21-28)
Oral contraception usage 5 (1-10) 7 (2.75-11) 5 (2-10) 5 (1-10) 5 (1-10) 5 (1-10)
Genetic predisposition score 0.98 (0.70-1.29) 0.95 (0.63-1.17) 0.95 (0.67-1.27) 0.83 (0.63-1.17) 1.17 (0.77-1.62) 0.90 (0.68- 1.33)
Oophorectomy 70 (35%) 0 (0%) 71 (12.96%) 88 (45.13%) 0 (0%) 102 (19.50%)
Mastectomy 35 (17.5%) 7 (6.19%) 49 (8.94%) 17 (9.74%) 0 (0%) 17 (3.25%)
Time of observation (years) 48.04 (42.74-53.76) 30.83 (28.0-38.90) 41.26 (35.83-49.38) 50.68 (44.77-57.70) 33.66 (29.13-42.49) 44.37 (38.02-51.78)
No. of events 92 (46.00%) 88 (77.88%) 321 (58.58%) 105 (53.85%) 72 (77.42%) 323 (61.76%)
  1. *includes also women with unknown menopausal stage status.
  2. **women may have had menopause after a breast cancer diagnosis.
\